Swetha Gopalakrishnan is an associate in Goodwin’s Business Law department and a member of its Technology and Life Sciences group. She joined Goodwin in 2022. Swetha represents private and public companies in broad range of transactions, including startup and formation, venture capital financings, mergers and acquisitions, capital market transactions, and corporate governance and securities compliance.
EXPERIENCE
Swetha’s recent representative experience, among others, includes:
- Medipost Co. Ltd., in its joint venture with Centre for Commercialization of Regenerative Medicine (CCRM) for the acquisition of OmniaBio, Inc.
- Greenlight Biosciences, Inc., in its take-private acquisition by a consortium led by Fall Line Endurance Fund, in an all-cash transaction of approximately $45.5 million
- Graphite Bio, Inc., in its reverse merger transaction with LENZ Therapeutics, Inc., including concurrent private placement offering
- Deciphera Pharmaceuticals, Inc., in its take-private acquisition by ONO Pharmaceutical Co., Ltd., for a total equity value of $2.4 billion
- Human Immunology Biosciences, Inc., in its sale to Biogen Inc. for a total value of $1.15 billion
- Prolaio, Inc. in its sale to Kardigan, Inc.
- BridgeBio Oncology Therapeutics, Inc., in its de-SPAC transaction with Helix Acquisition Corp. II, including concurrent private placement offering
- Deciphera Pharmaceuticals, Inc., in its follow-on offering of approximately $143.7 million
- Senti Biosciences, Inc., in its committed equity line financing of approximately $50 million
- Deciphera Pharmaceuticals, Inc., in its at-the-market (ATM) offering
- PepGen Inc., in its follow-on offering of approximately $80.1 million
- Vivani Medical, Inc., in its registered direct offering of approximately $15 million
- Vivani Medical, Inc., in its at-the-market (ATM) offering
- PepGen Inc. in its follow-on offering of approximately $115 million
- Senti Biosciences, Inc., in its PIPE financing of approximately $47.5 million
- CERo Therapeutics Holdings, Inc., in its follow-on offering of approximately $5 million
- Vivani Medical, Inc., in its private equity financing of approximately $8.25 million
- Vivani Medical, Inc., in its private equity financing of approximately $3 million
- Vedanta Biosciences, Inc., in its convertible note financing'
- CSA Medical, Inc., in its convertible note financings
- Alltrna, Inc., in its Series B financing
- ZymoChem, Inc., in its Series A financing
- CSA Medical, Inc., in its Series D financing
- Quotient Therapeutics, Inc., in its Series A-2 financing
- Numerous other private companies and venture capital firms in connection with equity and convertible debt financings
Professional Experience
Prior to joining Goodwin, Swetha was a Legal Consultant at Chugh, LLP, where she advised clients (corporations and individuals) on business transactions and business-related litigation matters. While attending law school, she worked as a Legal and Compliance Intern at a leading global investment firm, assisting the team with regulatory compliance as well as corporate matters.
Credentials
Education
JD2019
University of California College of the Law, San Francisco
BSL, LLB2016
Indian Law Society’s Law College
Admissions
Bars
- California